TheraRadar
← Back
Data updated: Jun 28, 2026

EPIZYME INC

Pharma
OncologyGastroenterology Execution: Fair

EPIZYME INC is a pharmaceutical company focused on Oncology, Gastroenterology. Key products include TAZVERIK.

2020
Since
1
Drugs
-
Trials
0
New Drugs (2yr)

FDA Novel Drug Designations

(2020)
1 Novel 1 First-in-Class 1 Orphan 1 Accelerated 1 Priority Review
See 1 novel approval →
2020 TAZVERIK (TAZEMETOSTAT HYDROBROMIDE) First-in-Class · Orphan · Priority Review · Accelerated

EPIZYME INC's Key Drugs

EPIZYME INC's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

EPIZYME INC's Recent FDA Approvals

New NDA/BLA approvals for EPIZYME INC over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

EPIZYME INC's Therapeutic Areas

EPIZYME INC's approved drugs and pipeline span 2 therapeutic areas, led by Oncology and Gastroenterology. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Oncology 97%
1 drugs Phase 3: 1 Phase 2: 3 Phase 1: 12
Gastroenterology 3%
0 drugs Phase 1: 1

EPIZYME INC's Top Competitors

EPIZYME INC's closest competitors by therapeutic-area and drug-target overlap include Johnson & Johnson, Bristol-Myers Squibb, and Takeda. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

Johnson & Johnson big-pharma
Oncology, Gastroenterology
Bristol-Myers Squibb big-pharma
Oncology, Gastroenterology
Takeda big-pharma
Gastroenterology, Oncology
PF PRISM CV big-pharma
Oncology, Gastroenterology
ASTELLAS specialty
Oncology, Gastroenterology

EPIZYME INC Pipeline Snapshot

EPIZYME INC has 17 active clinical programs from ClinicalTrials.gov — 1 Phase 3, 3 Phase 2 and 13 Phase 1.

1
Phase 3
3
Phase 2
13
Phase 1

Phase 3 Readout Calendar Pro

1 Phase 3 trial with confidence-graded primary completion dates.

Full calendar →
Q1 2027
Tazemetostat
Relapsed/Refractory Follicular Lymphoma
Estimated · fresh NCT04224493

Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • Top drug revenue breakdown
  • • Drug-level revenue analysis

Trial Catalysts

  • • Oncology pipeline focus
  • • 1 Phase 3 readout tracked
View readout calendar →

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 0/1 completed
  • • Speed: 42 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges